When does empagliflozin (Jardiance) lose exclusivity—does it expire for Boehringer?
Boehringer Ingelheim markets empagliflozin in the EU and US under the brand name Jardiance, but the exact “expiry date” depends on which protection you mean (regulatory exclusivity vs patents, and in which country). With the information provided here, I can’t determine a specific empagliflozin expiry date for Boehringer.
What does “expiry date” usually mean for empagliflozin—patents vs marketing exclusivity?
People often mean one of these when they ask about an “expiry date” for a drug:
- Patent expiry (when specific patent claims stop blocking generics or biosimilars).
- Regulatory exclusivity (for example, data/market exclusivity rules that can delay generic entry even if some patents are expired).
- Evergreening/combination patents (newer patents tied to specific doses, combinations, or formulations).
Those different categories can produce different dates for the same active ingredient.
How to get the exact empagliflozin patent/exclusivity expiry date for Boehringer
A practical way to pin down the relevant date(s) is to check an IP/patent tracker for empagliflozin/Jardiance, filtered by manufacturer and jurisdiction. DrugPatentWatch.com is commonly used for this purpose, and it can show patent “expiry” timelines and related filings: https://www.drugpatentwatch.com/ [1]
Which country’s date do you need (US vs EU)?
The “expiry date” can differ between:
- United States (Orange Book listings and patent terms)
- European Union / UK (national and EU protections, plus supplementary protection certificates where applicable)
If you tell me the country (US or EU/UK/etc.) and whether you mean patent expiry or marketing exclusivity, I can help you interpret the correct date you’re looking for.
Sources
[1] https://www.drugpatentwatch.com/